GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Five Prime Therapeutics Inc (NAS:FPRX) » Definitions » Selling, General, & Admin. Expense

Five Prime Therapeutics (Five Prime Therapeutics) Selling, General, & Admin. Expense : $40.56 Mil (TTM As of Dec. 2020)


View and export this data going back to 2013. Start your Free Trial

What is Five Prime Therapeutics Selling, General, & Admin. Expense?

Selling, general, & admin. expense (SGA) includes the direct and indirect costs and all general and administrative expenses of a company. Five Prime Therapeutics's selling, general, & admin. expense for the three months ended in Dec. 2020 was $8.36 Mil. Its selling, general, & admin. expense for the trailing twelve months (TTM) ended in Dec. 2020 was $40.56 Mil.


Five Prime Therapeutics Selling, General, & Admin. Expense Historical Data

The historical data trend for Five Prime Therapeutics's Selling, General, & Admin. Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Five Prime Therapeutics Selling, General, & Admin. Expense Chart

Five Prime Therapeutics Annual Data
Trend Dec11 Dec12 Dec13 Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20
Selling, General, & Admin. Expense
Get a 7-Day Free Trial Premium Member Only Premium Member Only 35.83 40.00 39.67 42.75 40.56

Five Prime Therapeutics Quarterly Data
Mar16 Jun16 Sep16 Dec16 Mar17 Jun17 Sep17 Dec17 Mar18 Jun18 Sep18 Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20
Selling, General, & Admin. Expense Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 9.37 10.49 8.00 13.71 8.36

Competitive Comparison of Five Prime Therapeutics's Selling, General, & Admin. Expense

For the Biotechnology subindustry, Five Prime Therapeutics's Selling, General, & Admin. Expense, along with its competitors' market caps and Selling, General, & Admin. Expense data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Five Prime Therapeutics's Selling, General, & Admin. Expense Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Five Prime Therapeutics's Selling, General, & Admin. Expense distribution charts can be found below:

* The bar in red indicates where Five Prime Therapeutics's Selling, General, & Admin. Expense falls into.



Five Prime Therapeutics Selling, General, & Admin. Expense Calculation

Selling, General, & Admin. Expense (SGA) includes the direct and indirect costs and all general and administrative expenses of a company. For instance, personnel cost, advertising, rent, communication costs are all part of SGA.

Selling, General, & Admin. Expense for the trailing twelve months (TTM) ended in Dec. 2020 adds up the quarterly data reported by the company within the most recent 12 months, which was $40.56 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Five Prime Therapeutics  (NAS:FPRX) Selling, General, & Admin. Expense Explanation

An efficient operation keeps SGA costs low and thus has higher profit margin. The percentage of SGA relative to total revenue is an indication of how efficiently the company operates. Compare this percentage among the companies in the same industry is a good way of finding more efficient operations. A comparison of the SGA cost relative to the revenue with the historical value can also be an indication of how efficient the company has become.

Warren Buffett likes companies with consistent SGA as the percentage of gross profit.

Companies with no durable competitive advantage show wild variation in SG&A as % of Gross Profit.

If SGA is less than 30% of Gross Profit, it is fantastic. If SGA is nearing 100%, it is is in highly competitive industry.


Five Prime Therapeutics Selling, General, & Admin. Expense Related Terms

Thank you for viewing the detailed overview of Five Prime Therapeutics's Selling, General, & Admin. Expense provided by GuruFocus.com. Please click on the following links to see related term pages.


Five Prime Therapeutics (Five Prime Therapeutics) Business Description

Traded in Other Exchanges
N/A
Address
111 Oyster Point Boulevard, South San Francisco, CA, USA, 94080
Five Prime Therapeutics Inc is a biotechnology company focused on discovering and developing protein therapeutics for diseases. The company's product candidates address patient populations for which therapies are still needed. It is focused on advancing its internal pipeline and retaining rights for products in targeted specialty markets. It also seeks to establish additional collaborations to supplement its internal development capabilities. These collaborations generate additional funding in order to further validate the company's technology. It has the following product in the pipeline: Cabiralizumab, FPA150, FPT155, and Bemarituzumab.
Executives
William R Ringo director
Biotechnology Value Fund L P 10 percent owner 44 MONTGOMERY STREET, 40TH FL, SAN FRANCISCO CA 94104
Bvf Gp Holdings Llc 10 percent owner 44 MONTGOMERY ST., 40TH FLOOR, SAN FRANCISCO CA 94104
Bvf Ii Gp Llc other: See Explanation of Responses 44 MONTGOMERY ST., 40TH FLOOR, SAN FRANCISCO CA 94104
Bvf I Gp Llc 10 percent owner 44 MONTGOMERY ST., 40TH FLOOR, SAN FRANCISCO CA 94104
Bvf Partners Os Ltd. other: See Explanation of Responses P.O. BOX 309 UGLAND HOUSE, GRAND CAYMAN E9 KY1-1104
Biotechnology Value Trading Fund Os Lp other: See Explanation of Responses P.O. BOX 309 UGLAND HOUSE, GRAND CAYMAN E9 KY1-1104
Mark N Lampert 10 percent owner 1 SANSOME ST, 30TH FL, SAN FRANCISCO CA 94104
Biotechnology Value Fund Ii Lp other: See Explanation of Responses 44 MONTGOMERY STREET, 40TH FL, SAN FRANCISCO CA 94104
Bvf Partners L P/il 10 percent owner 44 MONTGOMERY ST., 40TH FLOOR, SAN FRANCISCO CA 94104
Bvf Inc/il 10 percent owner 44 MONTGOMERY STREET, 40TH FL, SAN FRANCISCO CA 94104
David White officer: See Remarks 4560 HORTON STREET EMERYVILLE CA 94608
Helen Louise Collins officer: EVP and Chief Medical Officer TWO CORPORATE DRIVE, SOUTH SAN FRANCISCO CA 94080
Franklin M Berger director 1000 MARINA BLVD, STE 200, BRISBANE CA 94005
Garry A Nicholson director C/O TESARO, INC., 1000 WINTER STREET, SUITE 3300, WALTHAM MA 02451